1.12%
-1.93%
-4.91%
2.39%
20.06%
-8.91%
-26.33%
AI Spotlight on BSLN
Company Description
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives.It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan.The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia.
In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug.Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.
Market Data
| Last Price | 40.7 |
| Change Percentage | 1.12% |
| Open | 40.4 |
| Previous Close | 40.25 |
| Market Cap ( Millions) | 493 |
| Volume | 24851 |
| Year High | 47.95 |
| Year Low | 32.1 |
| M A 50 | 40.97 |
| M A 200 | 42.2 |
Financial Ratios
| FCF Yield | 1.86% |
| Dividend Yield | 0.00% |
| ROE | -19.22% |
| Debt / Equity | 669.89% |
| Net Debt / EBIDTA | 21283.44% |
| Price To Book | 29.3 |
| Price Earnings Ratio | -754.41 |
| Price To FCF | 53.69 |
| Price To sales | 3.31 |
| EV / EBITDA | 2334.69 |
News
- Jan -28 - Strong sales growth for Cresemba and Zevtera trigger further milestone payments to Basilea
- Jan -08 - Basilea provides portfolio update and outlook
- Dec -23 - Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics
- Dec -16 - Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States
- Sep -24 - Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis
- Sep -19 - Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding
- Sep -06 - Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea
- Aug -27 - European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea
- Aug -21 - Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
- Aug -20 - Recent Price Trend in Basilea Pharmaceutica (BPMUF) is Your Friend, Here's Why
- Aug -13 - Basilea reports strong 2024 half-year results and significantly increases full-year revenue and profit guidance
- Jun -20 - Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
- May -21 - Basilea Pharmaceutica (BPMUF) Is a Great Choice for 'Trend' Investors, Here's Why
- May -16 - Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
- May -03 - Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
- Apr -24 - Basilea shareholders approve all proposals of the board of directors at the annual general meeting
- Apr -09 - Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
- Apr -04 - Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications
- Mar -11 - Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
- Feb -13 - Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Innovative Pharmaceutical Products
Expected Growth : 5.0 %
What the company do ?
Basilea Pharmaceutica AG develops innovative pharmaceutical products, including antibiotics, antifungals, and cancer treatments, focusing on addressing unmet medical needs and improving patient outcomes.
Why we expect these perspectives ?
Basilea Pharmaceutica AG's 5.0% growth in innovative pharmaceutical products is driven by increasing demand for antibiotic resistance treatments, strategic partnerships for drug development, and expansion into emerging markets. Additionally, investments in research and development, as well as a strong pipeline of novel compounds, contribute to the company's growth momentum.
Basilea Pharmaceutica Ag Products
| Product Range | What is it ? |
|---|---|
| Cresemba | Cresemba is a prescription medicine used to treat adults with invasive aspergillosis, a fungal infection. |
| Zevtera | Zevtera is a prescription medicine used to treat adults with hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). |
| Ceftobiprole | Ceftobiprole is a cephalosporin antibiotic used to treat severe bacterial infections, including pneumonia and skin infections. |
Basilea Pharmaceutica AG's Porter Forces
Threat Of Substitutes
Basilea Pharmaceutica AG operates in a highly competitive industry, and there are many substitutes available for its products. However, the company's focus on innovation and R&D helps it to stay ahead of the competition.
Bargaining Power Of Customers
Basilea Pharmaceutica AG's customers are primarily healthcare professionals and patients, who have limited bargaining power due to the company's strong brand reputation and high-quality products.
Bargaining Power Of Suppliers
Basilea Pharmaceutica AG relies on a few key suppliers for raw materials and services, which gives them some bargaining power. However, the company's strong relationships with suppliers and its ability to negotiate prices help to mitigate this risk.
Threat Of New Entrants
The pharmaceutical industry is highly regulated, and new entrants face significant barriers to entry. However, the threat of new entrants is still high due to the potential for new companies to disrupt the market with innovative products and business models.
Intensity Of Rivalry
The pharmaceutical industry is highly competitive, with many established players competing for market share. Basilea Pharmaceutica AG faces intense competition from other companies, which can make it difficult to maintain market share and pricing power.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 109.71% |
| Debt Cost | 6.76% |
| Equity Weight | -9.71% |
| Equity Cost | 6.76% |
| WACC | 6.76% |
| Leverage | -1129.36% |
Basilea Pharmaceutica AG : Quality Control
Basilea Pharmaceutica AG passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CGEN | Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of … |
| GUBRA.CO | Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. The CRO segment offers … |
| HYL.BR | Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health, oncology, women's health, and other major therapeutic areas. The company … |
| MDWD | MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a … |
| BIOA-B.ST | BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Gubra
A-Score
1-Year Total Return ->
🥈
MediWound
A-Score
1-Year Total Return ->
🥉
Basilea Pharmaceutica
A-Score
1-Year Total Return ->
4
BioArctic
A-Score
1-Year Total Return ->
5
Compugen
A-Score
1-Year Total Return ->
6
